Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Files Japan NDA for Relugolix in Uterine Fibroids
March 1, 2018
- Janssen, Japan IBD Society Ink MOU on Crohn’s Disease Registry Study
March 1, 2018
- Hisamitsu’s Transdermal Parkinson’s Drug Hits Primary Endpoint
February 28, 2018
- FDA, EMA Accept Lusutrombopag Submissions, Priority Status Given in US: Shionogi
February 28, 2018
- Daiichi Sankyo Seeks Japan Approval for Hypertension Med Esaxerenone
February 28, 2018
- Kissei Makes Full Foray into IBD Arena with Rectabul, Set to Enrich “Unmet Needs” Portfolio
February 27, 2018
- Daiichi Sankyo to Set Up Specialty Marketing Unit for Oncology Products
February 27, 2018
- Sumitomo Dainippon, JCR Ink License Pact for BBB-Based CNS Drug Candidate
February 27, 2018
- Kyowa Kirin’s Burosumab Earns Conditional Approval in Europe
February 27, 2018
- Sumitomo Dainippon Sues 15 More Companies over Latuda Patent
February 27, 2018
- Liquid Tank Exploded at Kitasato Daiichi Sankyo Vaccine, No Pathogens Escaped
February 27, 2018
- 1st–in-Human Trial Begins for ADC DS-1062 in NSCLC: Daiichi Sankyo
February 26, 2018
- Mitsubishi Tanabe to Complete PIII for Plant-Derived Flu Vaccine in April, Obtain Top-Line Data around Summer
February 26, 2018
- Nomura Picked as Next Chief of Sumitomo Dainippon, Vows to Build Peripheral Healthcare Biz
February 26, 2018
- Sid Singh Named as New President of GSK Consumer Healthcare Japan
February 26, 2018
- Diagnogreen Applied for Evaluation of Blood Flow: Daiichi Sankyo
February 23, 2018
- Fujifilm to Set Up New Manufacturing Facility for Liposome Drugs, Operation Launch Targeted in Feb. 2020
February 23, 2018
- Pfizer Japan No Longer Disclosing Biosimilar Development Status for “Competitive Reasons”
February 23, 2018
- Sumitomo Dainippon’s iPSC-Based Parkinson’s Therapy Set for IIT Launch in FY2018
February 22, 2018
- Nippon Kayaku’s Novel Paclitaxel Form in Breast Cancer PII after PIII Miss
February 22, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…